Getein Biotech Inc (603387) — Cash Flow-to-Debt Ratio
Getein Biotech Inc (603387) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of CN¥100.90 Million could theoretically repay 0% of its total liabilities (CN¥1.04 Billion) in one year. See free cash flow generation of Getein Biotech Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Getein Biotech Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Getein Biotech Inc across 14 annual periods. Also explore Getein Biotech Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Getein Biotech Inc (2012–2025)
Year-by-year debt coverage analysis for Getein Biotech Inc. For market capitalisation and broader financial context, see Getein Biotech Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.44x | CN¥392.59 Million | CN¥896.55 Million | ▲ +2.1% |
| 2024 | 0.43x | CN¥423.00 Million | CN¥986.42 Million | ▲ +32.6% |
| 2023 | 0.32x | CN¥333.22 Million | CN¥1.03 Billion | ▼ -32.2% |
| 2022 | 0.48x | CN¥482.96 Million | CN¥1.01 Billion | ▼ -4.7% |
| 2021 | 0.50x | CN¥432.36 Million | CN¥863.90 Million | ▲ +87.8% |
| 2020 | 0.27x | CN¥185.47 Million | CN¥695.95 Million | ▼ -61.5% |
| 2019 | 0.69x | CN¥225.73 Million | CN¥325.98 Million | ▼ -30.7% |
| 2018 | 1.00x | CN¥187.10 Million | CN¥187.23 Million | ▼ -38.1% |
| 2017 | 1.61x | CN¥191.91 Million | CN¥118.87 Million | ▼ -5.6% |
| 2016 | 1.71x | CN¥155.91 Million | CN¥91.13 Million | ▼ -16.4% |
| 2015 | 2.05x | CN¥121.73 Million | CN¥59.48 Million | ▼ -14.3% |
| 2014 | 2.39x | CN¥98.53 Million | CN¥41.26 Million | ▲ +181.6% |
| 2013 | 0.85x | CN¥59.72 Million | CN¥70.42 Million | ▲ +75.1% |
| 2012 | 0.48x | CN¥23.80 Million | CN¥49.15 Million | — |